Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PreveCeutical Medical (CSE:PREV) has completed a program of development and evaluation regarding its cannabinoid soluble gel delivery system
  • soluble gel are administered nasally and leverage the nose-to-brain pathway by using the central nervous system
  • The company’s cannabinoid formulations are designed to treat a range of conditions, including epilepsy, neuropathic pain, multiple sclerosis and general pain
  • PreveCeutical is currently waiting to receive a final report from UniQuest, after which it will pursue intellectual property protection and clinical trials
  • PreveCeutical Medical (PREV) is currently up 16.67 per cent and is trading at 3.5 cents per share

PreveCeutical Medical (CSE:PREV) has completed a program of development and evaluation regarding its cannabinoid soluble gel delivery system.

The company’s proprietary soluble gel formulations are nasally administered and provide a sustained release that makes use of a direct nose-to-brain pathway.

The method bypasses the stomach and intestines, eliminating the first instance of metabolism, and is thought to dramatically improve bioavailability.

In addition, the gels remain in the nasal passage longer than traditional sprays, offering prolonged activity for up to seven days.

Soluble gels will also be universally patient-friendly, meaning that the formulations will be suitable for use by both children and adults.

Using the delivery system, PreveCeutical’s cannabinoid formulation has been designed to provide relief from a variety of conditions, including pain, inflammation, seizures and neurological disorders.

The company is currently awaiting a final report on the program from UniQuest, a branch of the University of Queensland that assist in the commercialisation of pharmaceutical and medical products.

Once the report has been received, PreveCeutical will move to secure intellectual property protection for its sol-gels, and intends to undertake a program of clinical trials.

Dr. Mak Jawadekar, President and Chief Scientific Officer of PreveCeutical Medical, was pleased to have concluded the program.

“Completion of the CBD Sol-Gel Program is a very significant milestone achievement for PreveCeutical.

“We are very excited about the therapeutic opportunities that will be derived from the program and look forward to progressing them through proof of concept studies,” he said.

PreveCeutical Medical (PREV) is currently up 16.67 per cent and is trading at 3.5 cents per share at 1:18pm EDT.

More From The Market Herald
Isracann Biosciences Inc. - CEO, Phil Floucault

" Isracann Bioscience (CSE:IPOT) facilitated genetics arrive in Israel

Isracann Bioscience (IPOT) announces that its first shipment of cannabis strains has cleared Israeli customs and are being raised as mother stock.
Entourage Health - CEO and Executive Chairman, George Scorsis.

" Entourage (TSXV:ENTG) launches medical cannabis marketplace for the uninsured

Entourage (ENTG) has launched Syndicate, a direct-to-patient medical cannabis marketplace.

" Simply Better Brands (TSXV:SBBC) PureKana Brand, grows 362 per cent vs. one year ago

Simply Better Brands (SBBC) expands its brick-and-mortar retail footprint, which reflects wholesalers, drug stores, convenience stores, as well as CBD specialty retail.
CENTR Brands - CEO, Arjan Chima

" CENTR Brands Corp. (CSE:CNTR) announces net sales growth of over 240 per cent in FY2022

CENTR Brands Corp. (CNTR) announced its audited financial results for the year ending May 31, 2022.